Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.